Kazia Therapeutics (KZIA.US) Latest Stock News - Major News Analysis - Longbridge

Quote List Quote List

Event Tracking

Nov8

Kazia Therapeutics released FY2025 9 Months Earnings on November 7, 2025 (EST) with actual revenue of USD 582.56K and EPS of USD -10.4709

04:00

Kazia Therapeutics released FY2025 Q4 earnings on November 7, 2025 (EST) with actual revenue of USD 589.43K and EPS of USD -2.4923

04:00

Kazia Therapeutics released FY2025 Annual Earnings on November 7 (EST), actual revenue USD 1.186 M (forecast USD 38.5 K), actual EPS USD -12.2472 (forecast USD -0.0173)

04:00

Kazia Therapeutics released FY2025 Q3 earnings on November 7 (EST), actual revenue USD 567.93K, actual EPS USD -2.4014

04:00

Nov3

Kazia Licenses PD-L1 Protein Degrader NDL2 from QIMR Berghofer

10:34

Oct28

CFA Analyst Recommends Buy for Kazia Therapeutics

10:22

Schedules & Filings

Schedules

Filings

Nov7

Earning Release(EST)

FY2025 Q4 Earning Release (USD) Revenue 589.43 K, Net Income -3.343 M, EPS -2.4923

Jun10

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 6.933 K, Net Income -3.252 M, EPS -3.8242

Apr17

Reverse Stock Split(EST)

1-for-5 Reverse Stock Split

View More

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change

View More